Reviva Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions for conditions with significant unmet medical needs
The company primarily concentrates on advancing its proprietary drug candidates through clinical trials to address psychiatric, neurological, and inflammatory disorders. Reviva utilizes its expertise in pharmacology to create novel treatment options that aim to improve the lives of patients by targeting specific mechanisms of disease while minimizing side effects associated with traditional therapies. Through its research and development efforts, Reviva seeks to make meaningful contributions to the field of medicine and enhance patient outcomes.
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reviva Pharmaceuticals Holdings, Inc. (“Reviva” or the “Company”) (NASDAQ: RVPH) on behalf of Reviva stockholders. Our investigation concerns whether Reviva has violated the federal securities laws and/or engaged in other unlawful business practices.
CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present at the Webull LIVE! Virtual Healthcare Investment Webinar on Wednesday, January 17, 2024.
